New Product: Beovu (brolucizumab) 120 mg/ml solution for injection in pre-filled syringe

This product is licensed for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults. Brolucizumab is a humanised monoclonal single chain FV antibody fragment targeting vascular endothelial growth factor (VEGF). It inhibits VEGF-A.

electronic Medicines compendium